Author

Matthew Leibovitch

Jewish General HospitalPrimary ORCID profile (0000-0002-9026-7141 · 2 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Matthew LeibovitchiD2 papers · Lady Davis Institute for Medical Research

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Alexander van OudenaardeniD· 1 shared Clara BonnetiD· 1 shared Daniel DurocheriD· 1 shared Daniëlle Bianchi· 1 shared Femke J. BakkeriD· 1 shared Frank SicheriiD· 1 shared H. Rudolf de BoeriD· 1 shared Jay Z. Yin· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexander van OudenaardenORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

WEE1 inhibitors trigger GCN2-mediated activation of the integrated stress response

Rinskje B. Tjeerdsma, Timothy F. Ng, Maurits Roorda, Daniëlle Bianchi, Sora Yang, Clara Bonnet, Michael A. VanInsberghe, Marieke Everts, Femke J. Bakker, H. Rudolf de Boer, Nathalie Moatti, Nicole Hustedt, Jay Z. Yin, Lisa Hoeg, Matthew Leibovitch, , Marcel A.T.M. van Vugt

This study shows WEE1 inhibitors trigger the integrated stress response via GCN2 activation, leading to translational shutdown, which can be mitigated by low-dose or combination treatments.

Nature Communications · Nov 24, 2025Peer-reviewedCancer Biology